Economic evaluation of therapeutic cancer vaccines and immunotherapy: A systematic review

Daniel M. Geynisman, Chun Ru Chien, Fabrice Smieliauskas, Chan Shen, Ya Chen Tina Shih

Research output: Contribution to journalReview article

13 Citations (Scopus)

Abstract

Cancer immunotherapy is a rapidly growing field in oncology. One attractive feature of cancer immunotherapy is the purported combination of minimal toxicity and durable responses. However such treatments are often very expensive. Given the wide-spread concern over rising health care costs, it is important for all stakeholders to be well-informed on the cost and cost-effectiveness of cancer immunotherapies. We performed a comprehensive literature review of cost and cost-effectiveness research on therapeutic cancer vaccines and monoclonal antibodies, to better understand the economic impacts of these treatments. We summarized our literature searches into three tables by types of papers: systematic review of economic studies of a specific agent, cost and cost-effectiveness analysis. Our review showed that out of the sixteen immunotherapy agents approved, nine had relevant published economic studies. Five out of the nine studied immunotherapy agents had been covered in systematic reviews. Among those, only one (rituximab for non-Hodgkin lymphoma) was found to be cost-effective. Of the four immunotherapy drugs not covered in systematic reviews (alemtuzumab, ipilimumab, sipuleucel-T, ofatumumab), high incremental cost-effectiveness ratio (ICER) was reported for each. Many immunotherapies have not had economic evaluations, and those that have been studied show high ICERs or frank lack of cost-effectiveness. One major hurdle in improving the cost-effectiveness of cancer immunotherapies is to identify predictive biomarkers for selecting appropriate patients as recipients of these expensive therapies. We discuss the implications surrounding the economic factors involved in cancer immunotherapies and suggest that further research on cost and cost-effectiveness of newer cancer vaccines and immunotherapies are warranted as this is a rapidly growing field with many new drugs on the horizon.

Original languageEnglish (US)
Pages (from-to)3415-3424
Number of pages10
JournalHuman Vaccines and Immunotherapeutics
Volume10
Issue number11
DOIs
StatePublished - Nov 1 2014

Fingerprint

Cancer Vaccines
Immunotherapy
Cost-Benefit Analysis
Costs and Cost Analysis
Economics
Therapeutics
Neoplasms
Therapeutic Human Experimentation
Pharmaceutical Preparations
Health Care Costs
Non-Hodgkin's Lymphoma
Biomarkers
Monoclonal Antibodies

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Immunology
  • Pharmacology

Cite this

Geynisman, Daniel M. ; Chien, Chun Ru ; Smieliauskas, Fabrice ; Shen, Chan ; Shih, Ya Chen Tina. / Economic evaluation of therapeutic cancer vaccines and immunotherapy : A systematic review. In: Human Vaccines and Immunotherapeutics. 2014 ; Vol. 10, No. 11. pp. 3415-3424.
@article{f0766165132545bc85ee2e4359dc264e,
title = "Economic evaluation of therapeutic cancer vaccines and immunotherapy: A systematic review",
abstract = "Cancer immunotherapy is a rapidly growing field in oncology. One attractive feature of cancer immunotherapy is the purported combination of minimal toxicity and durable responses. However such treatments are often very expensive. Given the wide-spread concern over rising health care costs, it is important for all stakeholders to be well-informed on the cost and cost-effectiveness of cancer immunotherapies. We performed a comprehensive literature review of cost and cost-effectiveness research on therapeutic cancer vaccines and monoclonal antibodies, to better understand the economic impacts of these treatments. We summarized our literature searches into three tables by types of papers: systematic review of economic studies of a specific agent, cost and cost-effectiveness analysis. Our review showed that out of the sixteen immunotherapy agents approved, nine had relevant published economic studies. Five out of the nine studied immunotherapy agents had been covered in systematic reviews. Among those, only one (rituximab for non-Hodgkin lymphoma) was found to be cost-effective. Of the four immunotherapy drugs not covered in systematic reviews (alemtuzumab, ipilimumab, sipuleucel-T, ofatumumab), high incremental cost-effectiveness ratio (ICER) was reported for each. Many immunotherapies have not had economic evaluations, and those that have been studied show high ICERs or frank lack of cost-effectiveness. One major hurdle in improving the cost-effectiveness of cancer immunotherapies is to identify predictive biomarkers for selecting appropriate patients as recipients of these expensive therapies. We discuss the implications surrounding the economic factors involved in cancer immunotherapies and suggest that further research on cost and cost-effectiveness of newer cancer vaccines and immunotherapies are warranted as this is a rapidly growing field with many new drugs on the horizon.",
author = "Geynisman, {Daniel M.} and Chien, {Chun Ru} and Fabrice Smieliauskas and Chan Shen and Shih, {Ya Chen Tina}",
year = "2014",
month = "11",
day = "1",
doi = "10.4161/hv.29407",
language = "English (US)",
volume = "10",
pages = "3415--3424",
journal = "Human Vaccines and Immunotherapeutics",
issn = "2164-5515",
publisher = "Landes Bioscience",
number = "11",

}

Economic evaluation of therapeutic cancer vaccines and immunotherapy : A systematic review. / Geynisman, Daniel M.; Chien, Chun Ru; Smieliauskas, Fabrice; Shen, Chan; Shih, Ya Chen Tina.

In: Human Vaccines and Immunotherapeutics, Vol. 10, No. 11, 01.11.2014, p. 3415-3424.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Economic evaluation of therapeutic cancer vaccines and immunotherapy

T2 - A systematic review

AU - Geynisman, Daniel M.

AU - Chien, Chun Ru

AU - Smieliauskas, Fabrice

AU - Shen, Chan

AU - Shih, Ya Chen Tina

PY - 2014/11/1

Y1 - 2014/11/1

N2 - Cancer immunotherapy is a rapidly growing field in oncology. One attractive feature of cancer immunotherapy is the purported combination of minimal toxicity and durable responses. However such treatments are often very expensive. Given the wide-spread concern over rising health care costs, it is important for all stakeholders to be well-informed on the cost and cost-effectiveness of cancer immunotherapies. We performed a comprehensive literature review of cost and cost-effectiveness research on therapeutic cancer vaccines and monoclonal antibodies, to better understand the economic impacts of these treatments. We summarized our literature searches into three tables by types of papers: systematic review of economic studies of a specific agent, cost and cost-effectiveness analysis. Our review showed that out of the sixteen immunotherapy agents approved, nine had relevant published economic studies. Five out of the nine studied immunotherapy agents had been covered in systematic reviews. Among those, only one (rituximab for non-Hodgkin lymphoma) was found to be cost-effective. Of the four immunotherapy drugs not covered in systematic reviews (alemtuzumab, ipilimumab, sipuleucel-T, ofatumumab), high incremental cost-effectiveness ratio (ICER) was reported for each. Many immunotherapies have not had economic evaluations, and those that have been studied show high ICERs or frank lack of cost-effectiveness. One major hurdle in improving the cost-effectiveness of cancer immunotherapies is to identify predictive biomarkers for selecting appropriate patients as recipients of these expensive therapies. We discuss the implications surrounding the economic factors involved in cancer immunotherapies and suggest that further research on cost and cost-effectiveness of newer cancer vaccines and immunotherapies are warranted as this is a rapidly growing field with many new drugs on the horizon.

AB - Cancer immunotherapy is a rapidly growing field in oncology. One attractive feature of cancer immunotherapy is the purported combination of minimal toxicity and durable responses. However such treatments are often very expensive. Given the wide-spread concern over rising health care costs, it is important for all stakeholders to be well-informed on the cost and cost-effectiveness of cancer immunotherapies. We performed a comprehensive literature review of cost and cost-effectiveness research on therapeutic cancer vaccines and monoclonal antibodies, to better understand the economic impacts of these treatments. We summarized our literature searches into three tables by types of papers: systematic review of economic studies of a specific agent, cost and cost-effectiveness analysis. Our review showed that out of the sixteen immunotherapy agents approved, nine had relevant published economic studies. Five out of the nine studied immunotherapy agents had been covered in systematic reviews. Among those, only one (rituximab for non-Hodgkin lymphoma) was found to be cost-effective. Of the four immunotherapy drugs not covered in systematic reviews (alemtuzumab, ipilimumab, sipuleucel-T, ofatumumab), high incremental cost-effectiveness ratio (ICER) was reported for each. Many immunotherapies have not had economic evaluations, and those that have been studied show high ICERs or frank lack of cost-effectiveness. One major hurdle in improving the cost-effectiveness of cancer immunotherapies is to identify predictive biomarkers for selecting appropriate patients as recipients of these expensive therapies. We discuss the implications surrounding the economic factors involved in cancer immunotherapies and suggest that further research on cost and cost-effectiveness of newer cancer vaccines and immunotherapies are warranted as this is a rapidly growing field with many new drugs on the horizon.

UR - http://www.scopus.com/inward/record.url?scp=84921753797&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84921753797&partnerID=8YFLogxK

U2 - 10.4161/hv.29407

DO - 10.4161/hv.29407

M3 - Review article

C2 - 25483656

AN - SCOPUS:84921753797

VL - 10

SP - 3415

EP - 3424

JO - Human Vaccines and Immunotherapeutics

JF - Human Vaccines and Immunotherapeutics

SN - 2164-5515

IS - 11

ER -